The BRCA test is a genetic test that looks for inherited mutations in two genes, BRCA1 and BRCA2, that dramatically raise a person’s lifetime risk of breast, ovarian, and several other cancers. Women who carry a harmful BRCA1 or BRCA2 mutation face a lifetime breast cancer risk somewhere between 45% and 82%, depending on the study and the specific mutation, compared to roughly 12% in the general population. The U.S. Preventive Services Task Force recommends that women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or with ancestry linked to known BRCA mutations, be assessed with a familial risk tool and referred for genetic counseling and, if warranted, testing. But the question of who should get tested has grown more complicated as testing has become cheaper and more widely available.
What BRCA Genes Do When They Work Properly
BRCA1 and BRCA2 are tumor suppressor genes. Their job is to help repair broken DNA and keep cells from growing out of control. When these genes function normally, they maintain genomic stability through several pathways, including fixing double-strand DNA breaks and activating cell cycle checkpoints that prevent damaged cells from dividing.1PubMed Central. The role of BRCA1 in DNA damage response Think of them as quality-control inspectors on an assembly line. When one of these genes is mutated, the inspection system breaks down. Damaged DNA accumulates, and cells are more likely to become cancerous.
How Much Do BRCA Mutations Raise Cancer Risk
The numbers vary depending on the study population and method, but the direction is always the same: risk goes up substantially. One widely cited study estimated the lifetime breast cancer risk among female mutation carriers at about 82%, with lifetime ovarian cancer risks of roughly 54% for BRCA1 carriers and 23% for BRCA2 carriers.2PubMed. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Other analyses place the range somewhat lower, with breast cancer risk estimated at 45–80% and ovarian cancer risk at 45–60% for BRCA1 carriers and 11–35% for BRCA2 carriers.3PubMed Central. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review The spread in these estimates reflects differences in how studies were designed and which families were included.
Risk also climbs steeply with age. A woman with a BRCA mutation has roughly a 20% chance of developing breast cancer by age 40, but that jumps to about 55% by age 60 and over 70% by age 70.3PubMed Central. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review For BRCA1 carriers, ovarian cancer risk rises sharply starting in a woman’s forties and increases by roughly ten percentage points each decade after that.
Who Should Consider Getting Tested
The USPSTF recommends that primary care clinicians use a brief familial risk assessment tool on women who have a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or who have ancestry associated with BRCA mutations. Women who screen positive on one of these tools should then be referred to genetic counseling and, if appropriate, genetic testing.4JAMA. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement The validated tools include the Ontario Family History Assessment Tool, the Manchester Scoring System, the Tyrer-Cuzick instrument, and several others. They all look for the same general red flags:
- Early-onset breast cancer: a diagnosis before age 50 in you or a close relative
- Bilateral breast cancer: cancer in both breasts
- Multiple cancer types: both breast and ovarian cancer in the same person or family
- Male breast cancer: any male family member diagnosed with breast cancer
- Clustered cases: multiple relatives on the same side of the family with breast cancer
- Ashkenazi Jewish ancestry: a population with a known higher frequency of specific BRCA mutations
The USPSTF does not recommend routine BRCA testing for women without these risk factors, because harmful mutations are uncommon in the general population and testing everyone would produce many more false alarms than actionable results.5United States Preventive Services Task Force. Clinical Summary: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
Ashkenazi Jewish Ancestry and Founder Mutations
Three specific BRCA mutations are far more common in people of Ashkenazi Jewish descent than in the general population. The frequency of these “founder mutations” in the Ashkenazi Jewish population is about 1 in 40 to 1 in 46, depending on the study.6Scientific Reports. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry That is dramatically higher than the BRCA mutation rate in the general population, which is estimated at somewhere around 1 in 300 to 1 in 500. In Israeli Ashkenazi women with ovarian cancer, founder mutations were found in 45% of cases, even in women with minimal family history.7PubMed Central. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
A complication worth knowing about: not everyone who carries an Ashkenazi Jewish founder mutation actually knows they have Jewish ancestry. In a large 23andMe dataset, about 21% of people carrying one of the three Ashkenazi founder variants did not report Jewish ancestry at all. Some of those individuals did have detectable Ashkenazi Jewish genetic ancestry they were unaware of, but roughly 8% had no detectable Ashkenazi ancestry whatsoever. This means ancestry-based screening guidelines will inevitably miss some carriers.6Scientific Reports. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry The same study found that about half of all BRCA carriers in their dataset would not have qualified for genetic testing based on family history alone.
What the Test Looks Like in Practice
Clinical BRCA testing typically involves a blood or saliva sample sent to a certified laboratory. The lab sequences the BRCA1 and BRCA2 genes looking for pathogenic variants, which are mutations known to disrupt the gene’s function. There are two broad contexts in which the test is done. Germline testing checks the DNA you were born with, using a blood or saliva sample, and tells you whether you inherited a BRCA mutation. Somatic tumor testing looks at the DNA of a tumor itself, because some cancers acquire BRCA mutations after birth even when the person’s inherited genes are normal. The distinction matters for treatment decisions.
For ovarian cancer specifically, guidelines from the American Society of Clinical Oncology recommend that all women diagnosed with epithelial ovarian cancer undergo germline BRCA testing, and those who do not carry a germline mutation should then have their tumors tested for somatic BRCA mutations.8PubMed Central. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline This two-step approach ensures that patients who could benefit from targeted therapies are not missed.
Many labs now offer multigene panel tests that check for mutations in BRCA1 and BRCA2 alongside other cancer-risk genes. These panels detect harmful BRCA mutations at the same rate as BRCA-only tests, but they also catch pathogenic mutations in other genes that raise cancer risk. In one study, about 4% of patients had a non-BRCA pathogenic mutation that a BRCA-only test would have missed entirely.9PubMed. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer
Making Sense of the Results
A BRCA test produces one of three general outcomes. A positive result means a known harmful mutation was found. A negative result means no harmful mutation was detected. And a third category, a variant of uncertain significance (VUS), means a genetic change was found but scientists do not yet know whether it actually increases cancer risk. This last category is more common than many people expect, and it is likely to grow as testing expands to larger and more diverse populations.10Annals of Oncology. BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance
A VUS result should not be treated like a positive. Most variants of uncertain significance will eventually turn out to be harmless, but the uncertainty can be distressing. Making major medical decisions based on a VUS, like undergoing preventive surgery, is generally not recommended. The good news is that VUS results are frequently reclassified over time as more data accumulates, so staying in touch with your genetic counselor allows you to learn if your variant is eventually upgraded or downgraded.11PubMed Central. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes
Direct-to-Consumer Tests Have Serious Limitations
Companies like 23andMe offer BRCA screening to consumers, but these tests check for only a handful of specific mutations, usually the three Ashkenazi Jewish founder variants. That means a negative result from a direct-to-consumer test does not rule out the thousands of other pathogenic BRCA mutations that exist. The tests also have troubling accuracy gaps outside their intended scope. In one clinical validation study, the false-positive rate for the three Ashkenazi founder mutations was low, under 1%. But for non-founder BRCA mutations and other cancer genes, the false-positive rate was staggeringly high, between 69% and 90%.12PubMed Central. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer In other words, if one of these tests tells you that you have a non-founder BRCA mutation, the odds are very high that it is wrong. Anyone who receives a positive result from a consumer test should always get confirmatory clinical testing before making any medical decisions.
Screening and Surveillance After a Positive Result
A confirmed positive result does not mean cancer is inevitable. It means you and your medical team shift into a high-surveillance mode. Current NCCN guidelines recommend that BRCA carriers without a cancer diagnosis begin clinical breast exams every six to twelve months starting at age 25, add annual breast MRI starting at age 25, and add annual mammography starting at age 30.13PubMed Central. Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer MRI catches cancers that mammography misses in dense breast tissue, which is why both imaging methods are used together rather than one replacing the other.
Preventive Surgery and Its Trade-offs
The most dramatic risk-reduction option is prophylactic surgery, either removing the breasts (prophylactic mastectomy), the ovaries and fallopian tubes (prophylactic salpingo-oophorectomy), or both. Modeling studies have estimated that 30-year-old BRCA carriers gain roughly three to five years of life expectancy from prophylactic mastectomy and a smaller but real gain from oophorectomy, with the benefits declining as the age at surgery increases.14PubMed. Decision Analysis–Effects of Prophylactic Mastectomy and Oophorectomy on Life Expectancy among Women with BRCA1 or BRCA2 Mutations Combining both surgeries at age 40 yielded the largest survival gains in one analysis: roughly a 24% absolute survival benefit for BRCA1 carriers and about 11% for BRCA2 carriers.15PubMed Central. Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
For women who have already been treated for breast cancer, prophylactic removal of the ovaries and tubes was strongly associated with improved overall survival among BRCA1 carriers in particular.16JAMA Surgery. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection The same benefit was not clearly seen in BRCA2 carriers, underscoring that the two genes are not interchangeable when making surgical decisions.
These are deeply personal decisions with real costs: surgical menopause, body image changes, and the finality of removing healthy organs. The timing of surgery, and whether to pursue it at all, is best worked through with a genetic counselor and a multidisciplinary medical team.
Chemoprevention Options
For carriers who are not ready for or do not want surgery, medications can partially reduce risk. Oral contraceptives have been associated with reduced ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, and breastfeeding and tubal ligation also showed a protective association for BRCA1 carriers specifically.17JNCI Journal of the National Cancer Institute. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis
Tamoxifen and raloxifene, drugs that block estrogen receptors, have also been studied in BRCA carriers. A recent meta-analysis found that these drugs reduced overall breast cancer risk by about 20%.18Scientific Reports. Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis However, the evidence is weaker when looking specifically at BRCA carriers rather than the general population. One observational study found a trend toward reduced breast cancer in BRCA carriers who used tamoxifen or raloxifene, but the result did not reach statistical significance.19PubMed. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation Chemoprevention is a reasonable discussion to have with your doctor, but it is not a substitute for the surveillance and surgical options that have stronger evidence behind them.
PARP Inhibitors and Why BRCA Status Matters for Treatment
Knowing your BRCA status is not only about prevention. If cancer does develop, a confirmed BRCA mutation opens the door to a class of drugs called PARP inhibitors. These drugs exploit a weakness specific to BRCA-deficient tumors. BRCA-mutated cancer cells already have a broken DNA repair system. PARP inhibitors knock out a second, backup repair pathway, leaving the cancer cell with no way to fix its DNA. The cell dies. Normal cells, which still have at least one working copy of BRCA, survive the drug because they can fall back on their intact repair pathway.20PubMed Central. PARP Inhibitors: The First Synthetic Lethal Targeted Therapy This approach is called synthetic lethality, and it is one of the clearest examples in oncology of a treatment designed around a patient’s specific genetic makeup.21PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings Multiple PARP inhibitors are now approved for use in BRCA-related breast and ovarian cancers, making genetic testing directly relevant to treatment planning.
Men and BRCA
BRCA testing is often framed as a women’s health issue, but men carry and transmit these mutations too, and they face their own cancer risks. Male BRCA2 carriers in particular have convincing evidence of increased risk for prostate cancer, pancreatic cancer, and male breast cancer.22PubMed Central. BRCA1, BRCA2 and Associated Cancer Risks and Management for Males: A Review Some studies suggest that the overall cancer risk for male BRCA2 carriers may actually exceed that of female carriers, with the relative risk being especially high before age 65.23PubMed. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature Despite this, men are far less likely to be offered or to pursue BRCA testing, partly because the cultural framing of the test is so heavily centered on breast and ovarian cancer. A man who knows his family carries a BRCA mutation should seriously consider testing, both for his own cancer screening and because he can pass the mutation to his children.
Telling Your Family and Cascade Testing
A BRCA mutation is inherited. If you carry one, each of your siblings and each of your children has a 50% chance of carrying it too. Testing relatives after an initial positive result is called cascade testing, and it is one of the most cost-effective strategies in cancer prevention because the family already knows exactly which mutation to look for. Studies show that people who test positive share their results with about 80% of their first-degree relatives, but the actual rate at which those relatives follow through with testing is much lower.24PubMed Central. Facilitated cascade testing (FaCT): a randomized controlled trial In one population-screening study, only about 58% of first-degree relatives and 26% of second-degree relatives actually underwent cascade testing.25Genetics in Medicine. Familial communication and cascade testing among relatives of BRCA population screening participants
The barriers are partly logistical and partly emotional. A scoping review found significant underuse of cascade testing despite more than two decades of available genetic testing, with psychosocial factors like family conflict, fear of results, and guilt about burdening relatives playing a major role.26PubMed. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review Male relatives are also less likely to get tested than female ones, which matters because, as noted above, male carriers face real health risks of their own.
The Emotional Side of Testing
Many people worry that getting a BRCA test will cause lasting psychological harm, especially if the result is positive. The research on this is more reassuring than you might expect. A meta-analysis found that carriers did experience a small uptick in anxiety shortly after learning their results, but their anxiety returned to pre-testing levels within a few months.27PubMed Central. Emotional Distress Following Genetic Testing for Hereditary Breast and Ovarian Cancer: A Meta-Analytic Review People who received negative results saw their anxiety drop in the short term and stabilize back to baseline over the longer term. Even those who received inconclusive results did not show significant anxiety changes compared to their pre-testing state.
A systematic review of cancer-affected carriers reached a similar conclusion: distress, anxiety, and depression symptoms increased in the first months after disclosure but did not persist at clinically meaningful levels over the intermediate and long term.28PubMed. Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review That said, individual responses vary. People who went into the test already underestimating their risk were more likely to struggle emotionally after an unexpected positive result, while those who overestimated their risk sometimes felt relief even after hearing they were carriers.29British Journal of Cancer. Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer Pre-test genetic counseling, which helps calibrate expectations, appears to be an important buffer.
Insurance and Legal Protections
Cost and fear of discrimination are among the most commonly reported barriers to testing. In one study of young breast cancer survivors, around 40% of untested women cited cost concerns, and about a third said their doctor simply had not recommended it.30PubMed Central. Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from using genetic test results against you. But GINA has gaps. It does not cover life insurance, disability insurance, or long-term care insurance. Awareness of GINA remains low: only about 27% of tested women and 15% of untested women in the same study knew the law existed. Insurance coverage for the test itself also varies. Private insurers generally cover BRCA testing for people who meet clinical criteria, while some public programs have been slower to provide coverage.31PubMed Central. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling
Reproductive Planning for BRCA Carriers
Carriers who want to have children face an additional decision: whether to use preimplantation genetic testing (PGT) during IVF to select embryos that do not carry the family’s BRCA mutation. This is technically feasible and increasingly available. In one clinical series covering more than a decade of experience, 86% of BRCA-positive patients who underwent IVF with PGT obtained at least one mutation-free embryo suitable for transfer, and about 59% of transferred embryos resulted in live births.32PubMed Central. Preimplantation genetic testing for monogenic disorders: clinical experience with BRCA1 and BRCA2 from 2010-2021 The proportion of embryos affected by the mutation was about what you would expect from basic inheritance patterns and did not differ based on whether the mutation came from the mother or the father.33PubMed Central. Outcomes of BRCA pre-implantation genetic testing according to the parental mutation origin: a cohort study
The ethics of PGT for BRCA are genuinely debated. Unlike testing for conditions that cause childhood disease, BRCA mutations raise the risk of cancers that typically develop decades later, and those cancers are increasingly preventable and treatable. Some ethicists question whether the physical demands, costs, and risks of IVF are justified to avoid a condition that may never manifest and is manageable if it does.34PubMed Central. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis Others argue that sparing a child from a lifetime of high-risk surveillance, surgical decisions, and cancer worry is reason enough. There is no consensus, and the decision is deeply personal.